Prosecution Insights
Prosecution Insights
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAPKOTA, SURAJ | 1 | — | — |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18365015 | COMPOSITION COMPRISING RAAV CONTAINING SOLUBLE VEGFR-1 VARIANT CDNA FOR TREATMENT OF MACULAR DEGENERATION | VIVLEMORE, TRACY ANN | 9d overdue |
| 18536423 | COMPOSITION FOR TREATING DIABETIC RETINOPATHY CONTAINING scAAV2-shmTOR-SD (CRG-01) | SAPKOTA, SURAJ | — |
| Art Unit | Apps |
|---|---|
| 4100 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18536423 | COMPOSITION FOR TREATING DIABETIC RETINOPATHY CONTAINING scAAV2-shmTOR-SD (CRG-01) | SAPKOTA, SURAJ | 4100 | §103§112 | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18365015 | COMPOSITION COMPRISING RAAV CONTAINING SOLUBLE VEGFR-1 VARIANT CDNA FOR TREATMENT OF MACULAR DEGENERATION | VIVLEMORE, TRACY ANN | 1638 | §103§112 | Non-Final OA | 9d overdue | Pending | Aug 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial